☆ 4.6 Article

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

BLOOD ADVANCES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Immunology

COVID-19 in Immunocompromised Hosts: What We Know So Far

Monica Fung et al.

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to significant morbidity and mortality globally. The impact of the disease on immunosuppressed patients, such as cancer patients and transplant recipients, remains unclear. Further research is needed to determine the risk of COVID-19 severity and death in immunocompromised patients.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Hematology

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Christopher Pleyer et al.

Summary: Treatment with BTK inhibitors resulted in a lower immune response rate to the HepB-CpG vaccine, but did not significantly affect the response rate to the RZV vaccine in CLL patients.

BLOOD (2021)

添加到收藏夹

Article Immunology

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Laurence Chu et al.

Summary: The study evaluated the safety and immunogenicity of the mRNA-1273 vaccine in healthy adults, showing significant immune responses to SARS-CoV-2 with acceptable safety profile. This vaccine induced higher antibody levels at a 100 mg dose, confirming its immunogenicity and safety for use in a 2-dose regimen.

VACCINE (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹

Letter Hematology

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos et al.

BLOOD (2021)

添加到收藏夹

Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin et al.

Summary: The study aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in cancer patients. The results showed poor efficacy of a single vaccine dose in cancer patients, with significantly increased immunogenicity in solid cancer patients after a vaccine boost at day 21. Therefore, it is recommended to prioritize cancer patients for an early second dose on day 21.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2021)

添加到收藏夹

Article Hematology

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Paola Ghione et al.

BLOOD (2021)

添加到收藏夹

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

添加到收藏夹

Letter Medicine, General & Internal

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Deborah Steensels et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange et al.

Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Hematology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Kazimieras Maneikis et al.

Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Sean H. Lim et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Article Immunology

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

Mounzer E. Agha et al.

Summary: It was found that about half of patients with hematological malignancies did not produce sufficient immune response after receiving two doses of vaccine, with B-cell chronic lymphocytic leukemia patients at a higher risk. Therefore, these patients need to continue taking protective measures. More research is needed to understand revaccination, boosters, and immune protection correlates.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Letter Medicine, General & Internal

Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine

Nathan E. Richards et al.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Hematology

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study

Ron Ram et al.

Summary: In this prospective evaluation, the BNT162b2 mRNA COVID-19 vaccine showed good tolerability and impressive immunogenicity in patients after allogeneic HCT or CART. While most adverse events were mild and transient, some significant hematologic events were observed, indicating the need for close monitoring of patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Oncology

Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

Astha Thakkar et al.

Summary: The study found differential rates of SARS-CoV-2 IgG seroconversion in cancer patients based on specific cancer types and therapy modalities. Patients with hematological malignancies, those receiving anti-CD-20 antibody therapy, and stem cell transplant patients had significantly lower seroconversion rates, while patients receiving immunotherapy, especially anti-PD-1/PD-L1 monoclonal antibodies, showed 100% seroconversion rates. These findings have implications for clinical monitoring and vaccination strategies to combat the COVID-19 pandemic.

NATURE CANCER (2021)

添加到收藏夹

Article Oncology

Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma

Clive S. Zent et al.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

COVID-19 in persons with haematological cancers

Wenjuan He et al.

LEUKEMIA (2020)

添加到收藏夹

Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

Hajime Yasuda et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)

添加到收藏夹

Review Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abi Vijenthira et al.

BLOOD (2020)

添加到收藏夹

Article Infectious Diseases

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew et al.

LANCET INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Immunology

Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies

Janie Parrino et al.

VACCINE (2017)

添加到收藏夹

Article Hematology

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

Hugues de Lavallade et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.